Hinova Details Progress of Candidate for AR+ Triple-Negative Breast Cancer

Chengdu Hinova Pharma received US FDA Fast Track designation for HP518, an investigational drug for Androgen-receptor positive (AR+) triple-negative breast cancer (TNBC). HP518 is a potent PROTAC AR degrader that has shown efficacy in AR+ TNBC. According to Hinova, the molecular subforms of TNBC are particularly aggressive forms of breast cancer, without targeted treatment options but accounting for approximately 15-20% of all breast cancer cases. They lack estrogen and progesterone receptors along with HER2 expression. However, up to 50% of TNBC cases express the androgen receptor, HP518’s potential target. More details....

Stock Symbol: (SHA: 688302)

Share this with colleagues: